AOD-9604 Adverse Events: What Studies Report

AOD-9604 is described in the literature as a synthetic peptide corresponding to the lipolytic carboxy-terminal region of human growth hormone, residues 176–191. Questions about its adverse-event profile run into an immediate problem: the indexed, peer-reviewed record contains very little structured safety reporting for this specific molecule. What exists is largely preclinical metabolic work, analytical chemistry, one cancer-cell experiment, and review articles that discuss AOD-9604 alongside other peptides rather than reporting primary adverse-event data.

This page summarises what those publications actually reported, organised by body system where the data allow it, and says plainly where no structured adverse-event data exist. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision.

What kind of evidence exists

The earliest metabolic characterisation in the verified set is a 2000 paper on metabolic studies of the synthetic lipolytic domain of human growth hormone, which investigated the fragment's metabolic actions in experimental models rather than cataloguing adverse events in patients (PMID 11146367). A 2007 review of currently used anti-obesity drugs and new compounds in clinical development placed AOD-9604-era candidates within the broader obesity pharmacotherapy pipeline, again without publishing a molecule-specific adverse-event table in its abstract scope (PMID 17971763).

A 2015 analytical paper reported on detection and in vitro metabolism of AOD9604, work oriented toward doping-control analysis and metabolic fate rather than clinical tolerability (PMID 25208511). A 2022 laboratory study reported that the human growth hormone fragment 176-191 peptide enhanced the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells, an in vitro cytotoxicity endpoint in a drug-delivery context (PMID 35783198).

More recently, review articles have addressed peptides of this class as a group. A 2026 review in sports medicine examined the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance (PMID 41966639), a 2026 orthopaedic review covered therapeutic peptides in orthopaedics including applications, challenges and future directions (PMID 41490200), and a 2026 endocrinology review described the emerging landscape of performance-enhancing peptides modulating the GH–IGF1 axis and the gap between clinical evidence and patient self-administration (PMID 42395176).

AOD-9604 Adverse Events: What Studies Report, by System

Metabolic and endocrine: What Studies Report

The metabolic question most often raised about growth-hormone-derived fragments is whether they reproduce the glucose and growth-axis effects of intact growth hormone. The 2000 metabolic study of the synthetic lipolytic domain (AOD9604) of human growth hormone examined the lipolytic actions of the fragment in experimental metabolic models, and researchers reported on its metabolic activity as distinct from the full-length hormone (PMID 11146367). That paper is a pharmacology study, not a tolerability study: it did not publish a structured list of treatment-emergent adverse events with incidence rates.

The 2007 review of anti-obesity drugs and compounds in clinical development discussed the class of agents then under investigation for obesity, but no AOD-9604-specific endocrine adverse-event frequencies appear within the scope of that review's abstract (PMID 17971763). The 2026 GH–IGF1 axis review framed self-administration of peptides acting on this axis as an area where clinical evidence lags behind real-world use (PMID 42395176).

Cell-level and oncology-adjacent findings: What Studies Report

One laboratory study in the verified set touched cancer biology directly. Researchers reported that the human growth hormone fragment 176-191 peptide enhanced the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells (PMID 35783198). That result was obtained in cultured cells as part of a drug-delivery investigation; it describes cytotoxicity toward a cancer cell line as an intended experimental outcome. It is not a human safety observation, does not establish a clinical risk, and does not establish the absence of one. Extrapolating cell-culture cytotoxicity data to adverse events in people is not supported by the design of that study (PMID 35783198).

Injection-site, dermatologic and immunogenic reactions: What Studies Report

No structured injection-site, rash, pruritus or hypersensitivity data for AOD-9604 appear in the verified papers summarised here. Peptide therapeutics as a class are discussed for immunogenicity and formulation challenges in the 2026 orthopaedic review of therapeutic peptides, which addressed challenges and future directions for the field rather than AOD-9604 reaction rates (PMID 41490200). Readers looking for incidence figures for local reactions with this specific peptide will not find them in this evidence set.

Cardiovascular, hepatic and renal: What Studies Report

The verified literature contains no organ-system safety reporting for AOD-9604 covering cardiovascular, hepatic or renal endpoints. The in vitro metabolism and detection work characterised metabolic transformation and analytical identification of AOD9604 rather than organ toxicity (PMID 25208511). Where no data exist, the honest statement is that none were reported — not that the compound was free of such effects.

Musculoskeletal and performance contexts: What Studies Report

Two 2026 reviews addressed peptides used in musculoskeletal and athletic settings. The sports-medicine review examined safety and efficacy across approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, a framing that explicitly separates regulator-approved products from those circulating without approval (PMID 41966639). The orthopaedic review covered therapeutic peptides in orthopaedics, including applications and challenges (PMID 41490200). Neither review is a substitute for primary adverse-event data on AOD-9604, and neither published incidence rates for it.

Study-by-study view

Why frequency figures are missing

Adverse-event percentages — the kind printed in drug labels, such as "headache, 12% versus 7% placebo" — come from controlled trials with pre-specified safety monitoring and systematic event capture. The verified publications summarised on this page are not of that design: they comprise preclinical metabolic work (PMID 11146367), analytical and in vitro metabolism research (PMID 25208511), a cell-culture drug-delivery experiment (PMID 35783198), and reviews (PMID 41966639, PMID 41490200, PMID 42395176). Reviews can describe known concerns, but they do not generate new incidence data.

Two consequences follow. First, the absence of reported adverse events in a preclinical or analytical paper is not evidence of tolerability; those studies were not designed to detect clinical events. Second, any numeric side-effect rate circulating for AOD-9604 outside the peer-reviewed literature cannot be traced to the studies above, and this page does not reproduce figures it cannot source.

Product identity and analytical considerations

Part of the safety discussion around unapproved peptides concerns what is actually in a given vial rather than the pharmacology of the molecule itself. Researchers characterised detection methods and in vitro metabolism for AOD9604, work that establishes how the peptide and its metabolic products can be identified analytically (PMID 25208511). The 2026 sports-medicine review's framing of approved versus unapproved peptide therapies is relevant here, because regulatory approval status determines whether manufacturing quality and post-marketing surveillance systems apply (PMID 41966639). The 2026 endocrinology review likewise distinguished clinical evidence from patient self-administration of GH–IGF1-axis peptides (PMID 42395176).

Limitations of this evidence summary

• No randomised controlled trial of AOD-9604 with published adverse-event tables appears in the verified set used for this page; the available primary work is preclinical or in vitro (PMID 11146367, PMID 25208511).
• The single cancer-cell finding describes enhanced cytotoxicity of a nanoparticle-delivered chemotherapeutic against MCF-7 cells and cannot be read as a clinical risk or benefit statement (PMID 35783198).
• Review-level sources describe the class and the evidence gap rather than AOD-9604 event rates (PMID 41966639, PMID 42395176).
• Older pipeline reviews reflect the state of obesity drug development at the time of writing and are not current safety assessments (PMID 17971763).

Related reading

For background on what AOD-9604 is, how it has been studied and the mechanisms researchers have described, see the overview page at /learn/aod-9604/.

References

• Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone (Hormone Research, 2000)
• Obesity: a review of currently used antiobesity drugs and new compounds in clinical development (Postepy Higieny i Medycyny Doswiadczalnej, 2007)
• Detection and in vitro metabolism of AOD9604 (Drug Testing and Analysis, 2015)
• Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells (Drug Design, Development and Therapy, 2022)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Frontiers in Endocrinology, 2026)